1. Overview and Comparison of Postmarketing Drug Safety Surveillance in Selected Developing and Well-Developed Countries

   • Sampada S. Vaidya
   • Jeff Jianfei Guo Bpharm
   • Michael Steinbuch

   Pharmacovigilance 30 December 2010 Pages: 519 - 533

2. Survey of Medical Liaison Practices 3: Assessing Practice Trends across the Pharmaceutical Industry

   • J. Lynn Bass
   • Christopher M. Marrone
   • Craig Klinger

   Drug Information 30 December 2010 Pages: 535 - 549

3. Medical Liaison Survey 4: Assessing Tools Used by Medical Liaisons, Clinical Trial Involvement, and Career Strategies

   • Craig J. Klinger
   • Christopher M. Marrone
   • J. Lynn Bass

   Drug Information 30 December 2010 Pages: 551 - 567

4. Pharmaceutical Medical Information Contact Centers: Results of Three Benchmarking Surveys

   • Pete Guillot
   • Stacey M. Fung

   Drug Information 30 December 2010 Pages: 569 - 579

5. Statistical Considerations for the Efficacy Assessment of Clinical Studies of Vulvar and Vaginal Atrophy

   • Ling Chen
   • Moh-Jee Ng
   • Anthony Orencia

   Biostatistics 30 December 2010 Pages: 581 - 588

6. Statistical Inference after an Adaptive Group Sequential Design: A Case Study

   • Lothar T. Tremmel

   Biostatistics 30 December 2010 Pages: 589 - 598

7. Blinded Sample Size Recalculation in Noninferiority Trials: A Case Study in Dermatology

   • Tim Friede
   • Holger Stammer

   Biostatistics 30 December 2010 Pages: 599 - 607

8. Nonparametric Sample Size Estimation for Sensitivity and Specificity with Multiple Observations per Subject

   • Fan Hu
   • William R. Schucany
   • Chul Ahn

   Biostatistics 30 December 2010 Pages: 609 - 616

9. Assessment of Consistency of Treatment Effects in Multiregional Clinical Trials

   • Hui Quan
   • Mingyu Li
   • Kimitoshi Ikeda

   Biostatistics 30 December 2010 Pages: 617 - 632

10. A Snapshot of the Evolution of Pharmaceutical Regulations in China and Hong Kong

    • Bing Bing Lin

    Regulatory Affairs 30 December 2010 Pages: 633 - 639

11. Understanding the Differences and Effectively Transitioning between the US Integrated Summaries of Effectiveness and Safety (ISE/ISS) and the CTD Summaries of Clinical Efficacy and Safety (SCE/SCS)

    • David N. Schwartz
    • Michael J. Umen
    • Mary Vanderhoof

    Regulatory Affairs 30 December 2010 Pages: 641 - 648